Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16695518 | 0.88 | NOTUM (0.74) | NOTUM | |
| SCHEMBL16695109 | 0.88 | NOTUM (0.74) | NOTUM | |
| SCHEMBL16695072 | 0.86 | DPP4 (0.52) | NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29604898 | 0.86 | DPP4 (0.52) | NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16695079 | 0.86 | DPP4 (0.52) | NOTUMNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16684692 | 0.86 | NOTUM (0.74) | NOTUMHSD11B1SCN9ANPC1RAB9A | |
| SCHEMBL16695121 | 0.84 | NOTUM (0.56) | NOTUMRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL16695095 | 0.84 | NOTUM (0.56) | NOTUMRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL19904544 | 0.83 | NOTUM (0.52) | NOTUMHSD11B1 | |
| SCHEMBL22491869 | 0.78 | NOTUM (0.59) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. | 2016-09-29 | — | — | US | disclosed |
| EP-3063141-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BioMarin Pharmaceutical Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| WO-2015065937-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | BIOMARIN PHARMACEUTICAL INC. (US) | 2015-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | NOTUM 454/4885HSD11B1 1103/4885SCN9A 1748/4885 |
| US-20160280643-A1 | N-(1-HYDROXY-3-(PYRROLIDINYL)PROPAN-2-YL)PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, UGCG, GBA2 | NOTUM 410/4885HSD11B1 1002/4885SCN9A 1573/4885 |
| US-10239832-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | NOTUM 410/4885HSD11B1 1002/4885SCN9A 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.